Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,751 total articles
Polyrizon Ltd., a Nasdaq-listed biotech company, has completed contracting with all five U.S. clinical sites for its first-in-human trial of NASARIX™, an innovative intranasal hydrogel-based allergy blocker for seasonal allergic rhinitis. This progress marks the study's move into patient pre-screening and enrollment, targeting up to 120 participant…
Purple Biotech Ltd. announced the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering tri-specific antibody constructs under its CAPTN-3 platform. This patent strengthens the company's intellectual property protection for its modular multispecific antibody technology designed to accelerate development of cancer i…
Palvella Therapeutics, a clinical-stage biotech company targeting rare skin diseases and vascular malformations, announced CEO Wes Kaupinen’s participation in two healthcare investor conferences in September 2026. The company highlighted its lead candidates, QTORIN™ 3.9% rapamycin anhydrous gel and QTORIN™ pitavastatin, which are investigational th…
Kyntra Bio, a biopharmaceutical company focused on oncology and rare diseases, announced management will present at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will cover company developments, including updates on their anemia treatment Roxadustat and Phase 2 ADC therapy FG-3246 for prostate cancer.
Telesat Corporation and Farcast have completed a successful demonstration of Farcast's electronically steered antenna technology using Telesat's LEO 3 test satellite. This milestone validates Farcast's architecture, which reduces size, weight, power, and cost while maintaining performance, and sets the stage for integrating this technology into a f…
BridgeBio Pharma announced they will present new late-breaking and longer-term data on oral infigratinib, a drug targeting achondroplasia, at the Annual European Society for Paediatric Endocrinology Meeting 2026. The data include results from the PROPEL 3 randomized controlled trial, longer-term safety and efficacy findings, and ongoing studies in …
OptimizeRx Corp. has appointed Troy Sarich, an expert in pharmaceutical commercialization and artificial intelligence, as a company advisor. Sarich's extensive experience at Johnson & Johnson and deep expertise in data analytics will help OptimizeRx enhance its healthcare technology solutions, facilitating better engagement between life sciences br…
Zevra Therapeutics, a commercial-stage biopharmaceutical company focused on rare diseases, announced that its executive leadership will present at three major healthcare investor conferences in New York in September 2026. These presentations aim to update investors on the company's progress and strategic direction. Zevra's lead product targets Niem…
Cronos Group Inc. announced an expansion of its Spinach® brand product line, introducing new edible multipacks featuring their first live resin gummy and new vape cartridge flavors. These additions build on Spinach®'s position as Canada's leading edible and vape brand, with planned broader national availability.
Algoma Steel Group Inc. reports progress on managing the unplanned outage at its Lake Superior Power generating facility. Through interim measures coordinated with Ontario's electricity operator, the company has resumed electric arc furnace production and is pursuing options to repair or replace the affected turbine. Algoma continues to evaluate pr…
FuelCell Energy reported Q3 FY2026 results highlighting a substantial increase in its backlog to $3.6 billion driven by new agreements including a major data center power supply contract. The company is progressing its manufacturing facility expansion to target 500 MW annualized capacity by 2028 and aims for positive Adjusted EBITDA by Q4 FY2027. S…
Quantum Cyber N.V., a Nasdaq-listed autonomous defense technology company, has appointed Tzvi Lev as Head of Sales for the Middle East to spearhead commercial expansion across the Gulf Cooperation Council and Israel. Leveraging Lev's extensive defense, diplomatic, and regional market experience, the company aims to convert its advanced autonomous d…
Daktronics, Inc., a leader in digital display technologies, announced fiscal 2027 first quarter results with a 21.2% increase in diluted EPS to $0.40 on 7.1% sales growth, achieving a 10.6% operating margin. The company maintained a product backlog exceeding $300 million for the sixth straight quarter and ended the quarter with a strong cash positi…
Edible Garden AG Incorporated has officially regained compliance with Nasdaq’s minimum bid price rule, enabling it to maintain its listing and focus on executing growth strategies including expanding its Webster City facility to manufacture ready-to-drink nutrition products and advancing its Farm-to-Formula® platform.
uniQure has submitted a Biologics License Application (BLA) to the U.S. FDA and a Marketing Authorisation Application (MAA) to the U.K.'s MHRA for its investigational gene therapy ifezuntirgene inilparvovec (AMT-130) for Huntington's disease. The applications are based on three-year Phase I/II study data showing slowed disease progression and the c…
Lifecore Biomedical has signed a significant agreement to perform tech transfer and commercial manufacturing for a commercially marketed injectable drug product from a global pharmaceutical company. This program, expected to generate revenue starting in 2028, further strengthens Lifecore's late-stage commercial pipeline and expands its customer bas…
Teva Pharmaceutical Industries announced positive topline Phase 2a study results for TEV-408, an investigational anti-IL-15 antibody. The drug showed statistically significant and clinically meaningful prevention of gluten-induced intestinal damage in celiac disease patients, with a favorable safety profile. TEV-408 also demonstrated a reduction in…
Lexeo Therapeutics, a clinical-stage genetic medicine company focused on cardiovascular disease treatments, announced its management team's participation in two investor conferences in September 2026. These engagements aim to update investors on the company's progress and pipeline developments, including novel therapies targeting genetic causes of …
Rapport Therapeutics, a clinical-stage biotech company focused on precision small molecule medicines for neurological and psychiatric disorders, will participate in upcoming investor events including the Cantor Global Healthcare Conference and TD Cowen Neuropsychiatry Summit. Management will discuss its RAP technology platform and lead drug candida…
MediWound Ltd., a biotech company specializing in enzymatic, non-surgical therapies for tissue repair, announced that CEO Ofer Gonen will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City. The event includes a fireside chat moderated by a senior healthcare analyst, providing a platform to discuss company devel…
Wrap Technologies announced the development of a new law enforcement doctrine and training curriculum designed to operationalize de-escalation utilizing its BolaWrap 150 device, recently classified by the ATF as an instrument of restraint rather than a firearm. The company has submitted the curriculum for independent validation and California Peace…
Can-Fite BioPharma reports that overall survival in its ongoing pivotal Phase III trial of Namodenoson for advanced hepatocellular carcinoma (HCC) is longer than initially expected, prompting plans to advance the interim analysis. While the trial remains blinded, this positive signal may indicate potential clinical benefit for patients with substan…
Aeluma, a NASDAQ-listed semiconductor company specializing in scalable photonic and electronic technologies, announced it will release its fourth quarter and fiscal year 2026 financial results after market close on September 16, 2026. The company will host an investor conference call the same day to discuss its financial performance and business ou…
Tonix Pharmaceuticals announced participation in Cantor's 2026 Global Healthcare Conference featuring a fireside chat with CEO Dr. Seth Lederman. The company showcased its focus on CNS disorders, infectious diseases, immunology, and rare diseases with marketed products including TONMYA® for fibromyalgia and migraine treatments, along with advancing…
Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on novel therapeutics targeting metabolic and fibrotic pathways, announced its management participation at the Cantor 2026 Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference in New York. The events include a fireside chat to be held an…
